Lexeo Therapeutics (LXEO) vs. Its Peers Critical Analysis

Lexeo Therapeutics (NASDAQ:LXEO) is one of 284 public companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its rivals? We will compare Lexeo Therapeutics to related companies based on the strength of its risk, analyst recommendations, earnings, profitability, institutional ownership, dividends and valuation.

Earnings & Valuation

This table compares Lexeo Therapeutics and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Lexeo Therapeutics	$650,000.00	-$66.39 million	-0.69
Lexeo Therapeutics Competitors	$548.36 million	-$37.50 million	-23.88

Lexeo Therapeutics’ rivals have higher revenue and earnings than Lexeo Therapeutics. Lexeo Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Lexeo Therapeutics and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexeo Therapeutics	0	0	6	0	3.00
Lexeo Therapeutics Competitors	1468	4598	12054	211	2.60

Lexeo Therapeutics currently has a consensus target price of $20.80, indicating a potential upside of 34.54%. As a group, “Biological products, except diagnostic” companies have a potential upside of 62.13%. Given Lexeo Therapeutics’ rivals higher possible upside, analysts clearly believe Lexeo Therapeutics has less favorable growth aspects than its rivals.

Insider & Institutional Ownership

60.7% of Lexeo Therapeutics shares are held by institutional investors. Comparatively, 50.9% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 4.5% of Lexeo Therapeutics shares are held by insiders. Comparatively, 16.1% of shares of all “Biological products, except diagnostic” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Lexeo Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lexeo Therapeutics	N/A	-155.79%	-51.08%
Lexeo Therapeutics Competitors	-5,023.37%	-218.44%	-47.57%

About Lexeo Therapeutics

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.